Dare Bioscience announced that additional data from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%, an investigational topical cream formulation of sildenafil being developed as an on-demand treatment for female sexual arousal disorder, has been published by The Journal of Sexual Medicine. “In this first-of-its-kind study in FSAD patients, we are very pleased to be able to share these data,” said Sabrina Martucci Johnson, President and CEO of Dare Bioscience. “Being able to show consistent results from patient reported outcome measures, regardless of whether she is recalling her experiences over the last month or the last day, provides important optionality as we consider how to clinically measure the impact of Sildenafil Cream on patients with FSAD.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DARE:
- Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
- Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update
- DARE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Daré Bioscience Regains Nasdaq Compliance, Advances Phase 3 Trials
- Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule